CNSY
CNSY clinical trials: CERENOME, INC.
Every trial on ClinicalTrials.gov where CERENOME, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CNSY on the catalyst calendar · CNSY registry changes
- Primary completion Jul 31, 2027Sponsor estimatePhase 1/Phase 2NCT07098806Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesCerenome · Leptomeningeal MetastasisRecruitingCNSYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1/Phase 2NCT01906385Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)Cerenome · GliomaActive, not recruitingCNSYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 19, 2026ActualPhase 1NCT05034497Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesCerenome · Leptomeningeal MetastasisCompletedCNSYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2028Sponsor estimatePhase 1NCT05460507Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL TreatmentCerenome · GliomaRecruitingCNSYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 1NCT07061626Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive...Cerenome · EpendymomaRecruitingCNSYLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner